C-reactive protein-to-lymphocyte ratio is a reliable marker in patients with COVID-19 infection: the CLEAR COVID study
Yükleniyor...
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Mexican Acad Surgery
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: COVID-19 infection is characterized with elevation of inflammatory markers in bloodstream. A novel inflammatory marker, C-reactive protein (CRP)-to-lymphocyte ratio (CLR), is suggested to be associated with inflammation. We aimed to compare the CLR values of the deceased COVID-19 patients to the CLR of survived subjects. Materials and Methods: The patients with COVID-19 whom presented to outpatient or inpatient clinics of AbantIzzet Baysal University Hospital were enrolled to the present retrospective study. Subjects were grouped as either deceased or survived. CLR values of the groups were compared. Results: Study cohort was consisted of 568 subjects in deceased and 4753 patients in survived group. Median CLR of the deceased and survived groups were 90 (0.2-1679)% and 11 (0.2-1062)%, respectively (p < 0.001). The sensitivity (75%) and specificity (70%) of CLR (> 23.4% level) in detecting mortality were higher than those of CRP and ferritin (AUC: 0.80, p < 0.001, 95% CI: 0.78-0.82). Conclusion: We suggest that elevated CLR levels in COVID-19 patients on admission should alert physicians for poor outcome.
Açıklama
Anahtar Kelimeler
COVID-19, Mortality, Inflammation, C-reactive Protein-to-lymphocyte Ratio, Clinical-Significance, Sars-Cov-2
Kaynak
Cirugia Y Cirujanos
WoS Q Değeri
Q4
Scopus Q Değeri
Q4
Cilt
90
Sayı
5
Künye
Demirkol, M. E., Bilgin, S., Kahveci, G., Kurtkulagi, O., Atak Tel, B. M., Duman, T. T., & Aktas, G. (2022). C-reactive protein-to-lymphocyte ratio is a reliable marker in patients with COVID-19 infection: the CLEAR COVID study. Cirugía y cirujanos, 90(5), 596-601.
